Press release
The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of ADCs.
Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.
An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
A list of key opinion leaders (KOLs) within this domain.
An insightful competitiveness analysis of biological targets.
An analysis of the partnerships that have been established in the recent past.
An analysis of the investments made.
A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April).
An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch.
An analysis of the key promotional strategies that have been adopted by the developers of marketed products.
An assessment of the various therapeutics that are being evaluated in combination with ADCs.
A review of the evolution of ADC conjugation technologies.
An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs.
An elaborate discussion on various factors that form the basis for the pricing of ADC products.
A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
A case study on companies offering companion diagnostics.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of payload
MMAE
DM4
Camptothecin
AM1
MMAF
Type of linker
VC
Sulfo-SPDB
SMCC
VA
Hydrazone linker
Others
Target Indications
Breast Cancer
Lymphoma
Leukemia
Urothelial cancer
Lung cancer
Ovaria cancer
Others
Target Antigen
CD30
HER2
CD22
CD33
Others
Small Molecule
Technology Providers
Seattle Genetics
ImmunoGen
StemCentRx
Immunomedics
Others
Key Geographies
North America
Europe
Asia Pacific
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Alan Burnett (Professor, School of Medicine, Cardiff University)
Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
Anthony DeBoer (Director, Business Development, Synaffix)
Christian Bailly (Director of CDMO, Pierre Fabre)
Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
John Burt (Chief Executive Officer, Abzena)
Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
Mark Wright (Site Head, Piramal Healthcare)
Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)
Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
Key companies covered in the report
Bristol Myers Squibb
AbbVie
Astellas Pharma
AstraZeneca
Daiichi Sankyo
Pfizer
Roche / Genentech
Synthon
Bayer HealthCare
Biotest Pharmaceuticals
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Other Offerings
1. ADC Contract Manufacturing Market (3rd Edition), 2018-2030
2. Gene Therapy Market (3rd Edition), 2019 - 2030
3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Roots Analysis here
News-ID: 2260895 • Views: …
More Releases from Roots Analysis
Respiratory syncytial virus infections are recognized among the prevalent respir …
Currently, several traditional techniques are available for treating these infections, although none of them have been competent enough to reduce the healthcare burden of RSV diseases. In order to address this, RSV vaccines emerged as a promising alternative, which provides active immunity against the RSV infections, thus protecting the vulnerable population. Further, by providing targeted immunity, these vaccines help reducing the severity of RSV infections and lower the hospitalization rates…
Rise in demand of glp-1 drugs for metabolic disorders.
In recent years, owing to its broader clinical potential in the treatment of obesity and type 2 diabetes, along with their proven efficacy in reducing cardiovascular risks, GLP-1 drugs market has garnered significant traction within the medical science domain.
Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions. This trend is expected…
Carbon footprint management market is Set to Soar to USD 55.9 Billion by 2035
Carbon footprint refers to the measurement of greenhouse gas emissions, expressed in carbon dioxide equivalent. It is released into the atmosphere either directly or indirectly through various activities, processes, or products. These emissions originate from diverse sources, including energy consumption, manufacturing processes, transportation networks, and waste management strategies.
The global carbon footprint management market, valued at USD 12.2 billion in 2024, is expected to reach USD 13.5 billion in 2025…
Gene switches have garnered significant attention from drug developers owing to …
The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035.
Driven by numerous developmental breakthroughs and encouraging study results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, in the treatment of various complex disorders, this…
More Releases for ADC
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.
New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to…
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates.
New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
"2023…
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment.
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by…
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market
Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
